Glucose-6-phosphatase (G6Pase) plays a central role in blood glucose homoeostasis, and insulin suppresses G6Pase gene expression by the activation of phosphoinositide 3-kinase (PI 3-kinase). Here, we show that the phorbol ester PMA decreases both basal and dexamethasone\cAMP-induced expression of a luciferase gene under the control of the G6Pase promoter in transiently transfected H4IIE hepatoma cells. This regulation was suppressed by the inhibitors of the mitogen-activated protein kinase\extracellular-signal-regulated kinase kinase (MEK), PD98059 and U0126, but not by the inhibitor of PI 3-kinase, LY294002. The co-expression of a constitutively active mutant of MEK mimicked the regulation of G6Pase promoter activity by PMA. The effect of PMA on both basal and induced G6Pase gene transcription was impaired by the overexpression of a
INTRODUCTION
Glucose-6-phosphatase (G6Pase) catalyses the hydrolysis of glucose 6-phosphate to glucose, which is the terminal step of both hepatic gluconeogenesis and glycogen breakdown [1] . G6Pase gene expression is induced by cAMP and glucocorticoids and is reduced by insulin. In Type II diabetes G6Pase gene expression is increased, which contributes to elevated hepatic glucose production [2] . Furthermore, the adenovirus-mediated overexpression of G6Pase in rat liver causes a disturbance of glucose and lipid homoeostasis, which is similar to early stage Type II diabetes [3] . Because of the potential involvement of an increased G6Pase gene expression in the development of metabolic changes associated with Type II diabetes [1] [2] [3] , the molecular pathways leading to a decrease in G6Pase gene expression are of particular interest. Most studies have focused on the signalling pathways involved in the regulation of G6Pase gene transcription by insulin. In itro models have shown that insulin decreases both basal and glucocorticoid\cAMP-induced G6Pase gene transcription by the activation of phosphoinositide 3-kinase (PI 3-kinase) [4, 5] and not the mitogen-activated protein kinase (MAPK) cascade Raf\MAPK kinase (MEK)\extracellular-signal-regulated protein kinase (ERK) [4] . The activation of PI 3-kinase leads via 3-phosphoinositide-dependent kinase 1 to the stimulation of protein kinase B (PKB) [6, 7] . PKB is partially responsible for the regulation of G6Pase gene transcription by insulin [5] . PKB regulates G6Pase gene transcription by the insulin-response unit (IRU) within the G6Pase promoter. The Abbreviations used : Bt 2 cAMP, N 6 ,2h-O-dibutyryl cAMP ; ERK, extracellular-signal-regulated protein kinase ; FKHR, forkhead in rhabdosarcoma ; G6Pase, glucose-6-phosphatase ; IRU, insulin-response unit ; MAPK, mitogen-activated protein kinase ; MEK, MAPK/ERK kinase ; MKP-1, MAPK phosphatase-1 ; PEPCK, phosphoenolpyruvate carboxykinase ; PI 3-kinase, phosphoinositide 3-kinase ; PKB, protein kinase B. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed (e-mail schmoll!mail.uni-greifswald.de).
dominant negative MEK construct, as well as by the expression of mitogen-activated protein kinase phosphatase-1. The mutation of the forkhead-binding sites within the insulinresponse unit of the G6Pase promoter, which decreases the effect of insulin on G6Pase gene expression, did not alter the regulation of gene expression by PMA. The data show that PMA decreases G6Pase gene expression by the activation of MEK and extracellular-signal regulated protein kinase. With that, PMA mimics the effect of insulin on G6Pase gene expression by a different signalling pathway.
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IRU is located between nt k196 and k156 in the human promoter [4, 8, 9] . It contains three forkhead-binding sites, with sequences similar to the insulin-response sequence of the phosphoenolpyruvate carboxykinase (PEPCK) promoter [8, 9] . The forkhead in rhabdosarcoma transcription factor (FKHR) stimulates the G6Pase gene expression by binding to the IRU. PKB suppresses the FKHR-transactivated G6Pase gene transcription by the phosphorylation of FKHR [5] . However, other, as yet unknown, mechanisms that are independent of PKB, forkhead proteins and the IRU also account for the effect of insulin on G6Pase gene transcription.
Phorbol esters, such as PMA, initiate signalling processes that are different from those activated by insulin. PMA imitates stimuli that act via the generation of diacylglycerol and the subsequent activation of conventional and novel isoforms of the protein kinase C family [10] . This leads to a stimulation of the MAPK cascade Raf\MEK\ERK, presumably by the direct phosphorylation of Raf [11, 12] . Raf phosphorylates and activates both isoenzymes MEK1 and MEK2. MEK stimulates the two isoenzymes ERK1 and ERK2 with high specificity. PMA imitates the effect of insulin on the eukaryotic initiation factor 4F assembly and general protein synthesis by the activation of the Raf\ MAPK\ERK module [13] . Like insulin, PMA is also able to inhibit PEPCK gene expression, but this effect is independent of MEK and ERK [14, 15] . However, PMA can also exhibit effects opposite to insulin, e.g. the gene expression of the insulin-likegrowth-factor-binding protein-1 is suppressed by insulin, but induced by PMA [16] .
In the present study we report that PMA suppresses G6Pase gene transcription ; however, in contrast with insulin, PMA decreases G6Pase gene expression by the activation of MEK and ERK.
EXPERIMENTAL Materials
LY294002, PD98059, U0126 and PMA were obtained from Calbiochem. Myelin basic protein and Protein A-Sepharose were from Sigma. Anti-ERK2 and anti-PKBα antibodies were from Santa Cruz Biotechnology. Radioisotopes were purchased from Amersham Pharmacia Biotech. All other chemicals were purchased in the highest grade available from either Merck or Roche.
Plasmids
The G6Pase reporter gene construct G6Pase(k1227\j57) was created by cloning the human G6Pase promoter fragment k1227 to j57 into the promoterless luciferase reporter gene vector pGL3 basic (Promega) [5] . To generate the promoter gene construct G6Pase(k1227\j57\IRUmut) the forkheadbinding sites of the IRU were mutated within the vector G6Pase(k1227\j57) from k196 5h-CGATCAGGCTGTTT-TTGTGTGCCTGTTTTTCTATTTTACG-3h k156 into 5h-CGATCAGGCTCGAGTTGTGTGCCTCTTTTTCTCTTT-TACG-3h (mutated nucleotides are underlined), as described in [5] . This prevents the regulation of G6Pase promoter activity by PKB and FKHR and also impairs the insulin effect [5] . The expression vectors for the wild-type MAP kinase phosphatase-1 (pSG-MKP-1) and the catalytically inactive mutant (pSG-MKP-1-CS) were kindly provided by Dr N. Tonks [17] . The vectors expressing catalytically inactive, dominant negative MEK-SA222 and constitutively active MEK-SS\DD were generously provided by Dr G. Pages and Dr J. Pouyssegur [18] .
Transfections
H4IIE cells were transfected with 8.5 µg\dish of the reporter vector, 0.5 µg\dish of pRL-TK control plasmid (Promega) and, where indicated, with 2 µg\dish of the expression vectors for MEK or MKP-1 using the calcium phosphate\DNA coprecipitation method, essentially as described in [5] . After the glycerol shock, the cells were serum starved for 1 h and then incubated in the presence or absence of dexamethasone (1 µM), N',2h-O-dibutyryl cAMP (Bt # cAMP ; 500 µM) and PMA (1 µM). In some experiments transfected cells were incubated for 10 min with the PI 3-kinase inhibitor LY294002 (100 µM) and for 60 min with the MEK inhibitors PD98059 (50 µM) or U0126 (20 µM) before the other hormones were added. After 20 h cell extracts were prepared and luciferase activities were determined using the dual luciferase assay reagent (Promega), according to the manufacturer's instructions. All experiments were performed at least three times each in triplicate with at least two different DNA preparations. Statistical analysis was performed using the t test for unpaired data.
Immunoprecipitation and in vitro kinase assay H4IIE cells were serum starved for 16 h and incubated in the presence or absence of LY294002 (100 µM), PD98059 (50 µM) and U0126 (20 µM) as described above, prior to the addition of PMA (1 µM), insulin (5 nM), dexamethasone ( [7] . In control assays the respective substrates, myelin basic protein or Crosstide peptide, were omitted. The assays were terminated by spotting on phosphocellulose paper. All papers were washed five times with 0.5 % (v\v) phosphoric acid to remove ATP and once in acetone. Radioactivity was measured by liquid-scintillation counting. One unit of protein kinase activity was the amount that led to the incorporation of 1 nmol phosphate into the substrate in 1 min.
Western-blot analysis
H4IIE cell lysates were prepared as described above. Equal amounts of cell lysate protein were separated by SDS\PAGE (12.5 %) and transferred on to nitrocellulose membranes. Even transfer was verified by Ponceau staining. Membranes were blocked in 3 % BSA in TBS-T [15 mM Tris\HCl, pH 7.4, 150 mM NaCl, 0.1 % (v\v) Triton X-100] for 30 min. The blots were incubated with anti-phospho ERK1\2 antibodies (Cell Signaling, Beverly, MA, U.S.A.) in blocking buffer overnight at 4 mC. After washing the blots three times with TBS-T, they were incubated with peroxidase-conjugated anti-rabbit Ig for 1 h and then washed again five times with TBS-T. Detection was performed by ECL2 (Amersham Pharmacia). Subsequently, the blots were stripped and re-probed with an antibody specific for ERK1\2 (Cell Signaling).
RNA isolation and Northern blots
H4IIE cells (800 000) were serum starved for 16 h and incubated in the presence or absence of dexamethasone (1 µM), Bt # cAMP (500 µM) and PMA (1 µM) for 5 h. In some experiments, transfected cells were incubated with the inhibitors PD98059 (50 µM) and U0126 (20 µM) as described, before the other hormones were added. RNA was isolated using the RNeasy Minikit (Qiagen). A 15 µg portion of total RNA was separated on a 1 % (w\v) agarose\6.6 % (v\v) formaldehyde denaturing gel and transferred on to nylon membranes by vacuum blotting. The transferred RNA was cross-linked by UV light. The membrane was prehybridized for 3 h at 42 mC in hybridization buffer [50 % (v\v) formamide, 100 µg\ml salmon sperm DNA, 1 M NaCl, 100 mg\ml dextran sulphate and 1 % (w\v) SDS]. It was then hybridized overnight at 42 mC using random primed $#P-labelled probe for G6Pase (Prime-a-gene ; Promega) in hybridization buffer. The membrane was washed at 65 mC for 30 min twice with 300 mM NaCl, 35 mM sodium citrate, 0.1 % (w\v) SDS, pH 7.2, and twice with 30 mM NaCl, 3.5 mM sodium citrate, 0.1 % (w\v) SDS, pH 7.2. Transcripts were visualized and quantified by phosphorimaging. Subsequently, the blots Glucose-6-phosphatase gene expression and PMA were rehybridized using a random primed $#P-labelled probe for actin.
RESULTS

PMA inhibits G6Pase gene expression
The transcription of the G6Pase gene is induced by dexamethasone and cAMP and decreased by insulin in hepatic cells [1, 4, 5, 8] . In order to study the regulation of the G6Pase promoter by PMA, H4IIE hepatoma cells were transiently transfected with a luciferase expression vector under control of the G6Pase promoter fragment k1227\j57. The administration of PMA was able to decrease both basal and Bt # cAMP\dexamethasone-induced G6Pase luciferase activity ( Table 1 ). With that, PMA exhibited an insulin-mimetic effect. However, the inhibitory effect of PMA was less than that of insulin. PMA inhibited the basal and induced gene transcription by approx. 34p5 % and 67p6 % respectively, compared with the insulin effect of approx. 84p2 % and 90p5 % respectively. The PI 3-kinase inhibitor LY294002 did not significantly affect the inhibition of the basal G6Pase promoter activity by PMA, but partially prevented the suppression of induced gene transcription by the phorbol ester. In parallel incubations, LY294002 almost completely blocked the regulation of the G6Pase promoter by insulin, as has been described previously [5] . These results indicate that, in contrast with the regulation by insulin, PI 3-kinase does not have a central role in the regulation of G6Pase gene transcription by PMA.
Inhibition of MEK blocks the PMA effect on G6Pase gene expression
We then analysed the potential involvement of the MEK\ERK cascade in the inhibition of G6Pase gene transcription by PMA. To do this, H4IIE cells were transiently transfected with the G6Pase promoter construct G6Pase(k1227\j57) and preincubated with either PD98059 or U0126 prior to the application of the phorbol ester. As shown in Figure 1 , both inhibitors of MEK blocked the regulation of basal ( Figure 1A ) as well as Bt # cAMP\dexamethasone-induced ( Figure 1B ) G6Pase promoter activity. It has been previously reported [4] that PD98059 does not significantly block the regulation of induced G6Pase gene expression by insulin. We confirm this data and show, furthermore, that PD98059 also does not block the Table 1 Suppression of basal and Bt 2 cAMP/dexamethasone-induced G6Pase promoter activity by PMA and insulin H4IIE cells were co-transfected with 8.5 µg/dish of the promoter plasmid G6Pase(k1227/ j57) and 0.5 µg/dish of pRL control plasmid. Cells were incubated with or without PMA (1 µM), insulin (5 nM) and the PI 3-kinase inhibitor LY294002 (100 µM) as indicated, and in the absence (basal) or presence (induced) of the combination of Bt 2 cAMP (500 µM)/ dexamethasone (1 µM). Data are presented as meanspS.E.M. (n l 3) of fold-activation relative to either basal or the induced luciferase activity, which was set as 100. Bt 2 cAMP/dexamethasone led to 8.0p0.9-fold induction of the promoter activity. *P 0.05 compared with the basal or induced activity. regulation of basal promoter activity by insulin. In addition, the structurally unrelated MEK inhibitor U0126 is also unable to alter the regulation of both basal and induced G6Pase promoter activity by insulin. The data suggest that the activation of MEK is not involved in the regulation of G6Pase gene expression by insulin, but is essential for the suppression of G6Pase gene transcription by PMA.
PMA reduces G6Pase mRNA levels by the activation of MEK
We next studied whether, in H4IIE cells, the expression of endogenous G6Pase is also regulated by PMA via the activation of MEK and ERK. Northern-blot analysis (Figure 2) showed that, similar to the regulation of the G6Pase promoter construct, PMA decreased the amount of basal as well as Bt # cAMP\ dexamethasone-induced endogenous G6Pase transcript. Again, this suppression by PMA was impaired by the MEK inhibitors PD98059 and U0126. This indicates that MEK contributes to the regulation of the amount of endogenous G6Pase transcript by PMA. Furthermore, we observed an induction of basal and Bt # cAMP\dexamethasone-induced G6Pase gene expression by PD98059 in the absence of PMA.
Figure 2 MEK inhibitors PD98059 and U0126 suppress the PMA effect on the amount of basal and Bt 2 cAMP/dexamethasone-induced G6Pase mRNA transcript in H4IIE cells
H4IIE cells were incubated in the presence or absence of PMA (1 µM) and the MEK inhibitors PD98059 (50 µM) and U0126 (20 µM) and in the absence or presence of Bt 2 cAMP (DBCA ; 500 µM)/dexamethasone (Dexa ; 1 µM). RNA (15 µg) was electrophoresed, transferred on to nylon membranes and hybridized using a random primed 32 P-labelled probe for G6Pase. Actin was used as a normalization control. (A) Northern blot, (B) densitometric analysis of three Northern blots (meanspS.E.M. ; n l 3). The G6Pase mRNA level is shown relative to that under basal conditions. *P 0.05 compared with basal expression, **P 0.05 compared with expression in the presence of only dexamethasone and Bt 2 cAMP.
Table 2 Regulation of basal and induced G6Pase promoter activity by a constitutively active MEK mutant and a dominant negative MEK mutant
H4IIE cells were co-transfected with 8.5 µg/dish of the promoter plasmid G6Pase(k1227/j57), 0.5 µg/dish of pRL control plasmid and 2 µg/dish of either dominant negative MEK (MEK-SA222), constitutively active MEK (MEK-SS/DD) or a vector control (pECE). Cells were incubated with or without PMA (1 µM) as indicated, and in the absence (basal) or presence (induced) of Bt 2 cAMP (500 µM) and dexamethasone (1 µM). Data are presented as meanspS.E.M. (n l 3) of fold-activation relative to either basal or the induced luciferase activity after the co-expression of the vector control, which was set as 100. *P 0.05 compared with the respective promoter activity in the absence of PMA, **P 0.05 compared with the basal or induced activity after the co-expression of the vector control in the absence of PMA, ***P 0.05 compared with the PMA-inhibited activities after the coexpression of the constitutively active mutant and the vector control, †P 0.05 compared with the respective promoter activity without PMA and to the PMA-inhibited activities after the coexpression of the constitutively active mutant and the vector control.
Co-expressed vector Treatment
Relative promoter activity H4IIE cells were co-transfected with 8.5 µg/dish of the promoter plasmid G6Pase(k1227/j57), 0.5 µg/dish of pRL control plasmid and 2 µg/dish of either wild-type pSG5-MKP-1, the catalytically inactive MKP-1 mutant (pSG5-MKP-CS) or a vector control (pSG5). Cells were incubated with or without PMA (1 µM) as indicated, and in the absence (basal) or presence (induced) of Bt 2 cAMP (500 µM) and dexamethasone (1 µM). Data are presented as meanspS.E.M. (n l 3) of fold-activation relative to either basal or the induced luciferase activity, after the co-expression of the vector control, which was set as 100. *P 0.05 compared with the basal or induced activity after the co-expression of the respective vector in the absence of PMA, **P 0.05 compared with the PMA-inhibited activities after the coexpression of the constitutively active mutant and the vector control, †P 0.05 compared with the respective promoter activity without PMA and to the PMA-inhibited activities after the coexpression of the constitutively active mutant and the vector control.
Relative promoter activity 
Overexpression of MEK inhibits G6Pase gene expression
In order to study the role of MEK in the suppression of G6Pase promoter activity further, H4IIE cells were co-transfected with plasmids expressing either a constitutively active or a catalytically inactive MEK [18] together with the G6Pase promoter vector. The co-expression of the active MEK construct decreased both basal and Bt # cAMP\dexamethasone-induced luciferase expression compared with the co-expression of either the catalytically inactive MEK-SA222 construct or the vector control ( Table 2 ). With that, the overexpression of MEK mimicked the PMA effect, indicating that MEK activation is sufficient to suppress G6Pase gene transcription. The co-expression of the construct MEK-SA222, which exhibits a dominant negative effect on the activation of endogenous MEK [18] , completely blocked the regulation of basal G6Pase gene transcription by PMA. However, this construct did not fully suppress the effect of PMA on induced G6Pase promoter activity. Nevertheless, the results suggest that the activation of MEK is not only sufficient, but also contributes significantly to the suppression of G6Pase gene transcription by PMA, and support the data obtained with the MEK inhibitors.
Overexpression of MKP-1 impairs the PMA effect on G6Pase gene expression
MEK activates ERK1\2 with high specificity [12] . MKP-1 dephosphorylates and thereby inactivates ERK, although other kinases can also be dephosphorylated by MKP-1 [12, 17] . In order to support the hypothesis that PMA inhibits G6Pase gene transcription by the activation of the MEK\ERK cascade, H4IIE cells were co-transfected with the G6Pase promoter construct together with vectors expressing either wild-type MKP-1 or the catalytically inactive MKP-1-CS mutant [17] . Compared with the co-transfection of either the catalytically inactive mutant or the vector control, the transfection of wild-type MKP-1 completely blocked the PMA effect on basal promoter activity and suppressed the PMA effect on the induction of promoter activity by Bt # cAMP\dexamethasone in part (Table 3) . These results Glucose-6-phosphatase gene expression and PMA 
Figure 3 Regulation of ERK1/2 phosphorylation by PMA and insulin
Serum-starved H4IIE cells were incubated with or without the MEK inhibitors PD98059 (50 µM) and U0126 (20 µM) and for 10 min in the presence or absence of PMA (1 µM), insulin (5 nM), and the combination of Bt 2 cAMP (DBCA ; 500 µM) and dexamethasone (Dexa ; 1 µM) as indicated. Cell lysates were electrophoresed by SDS/PAGE and transferred on to nylon membranes. Western blots were performed using an antibody specific for phosphorylated ERK1/2. To control for loading, blots were subsequently incubated with anti-ERK1/2 antibody.
provide further evidence for the involvement of the MEK\ERK cascade in the regulation of G6Pase gene expression by PMA.
Regulation of ERK and PKB activities by PMA and insulin
The data presented so far indicate that PMA inhibits G6Pase gene expression in a different way to insulin by the activation of MEK and ERK, and not of PI 3-kinase. In order to further elucidate the molecular background of this differential regulation, we studied the effect of PMA and insulin on the activities of ERK and PKB in H4IIE cells. The activation of PKB is an event downstream of PI 3-kinase stimulation. We analysed ERK activities by an in itro kinase assay using immunoprecipitated ERK2 with basic myelin protein as the substrate (Table 4) , and in some cases by Western blotting of cell lysates using an antibody specific for phosphorylated ERK1\2 (Figure 3 ). Both approaches led to similar results. Under our experimental conditions, the incubation of H4IIE for 10 min with PMA increased the basal ERK2 activity of 1.5p0.6 m-units\mg of protein by approx. 20-fold. This activation of ERK2 was almost completely blocked by the inhibitors of MEK PD98059 and U0126. This is consistent with the notion that activation of ERK1\2 is mediated by the activation of MEK-1\2. The addition of Bt # cAMP and dexamethasone reduced the activation of ERK2 by PMA, but did not disrupt the ability of the MEK inhibitors to decrease ERK2 activation. Only an approx. 4-fold activation of ERK2 could be detected after the incubation with PMA for 120 min. After 1200 min no activation was detected. The incubation of H4IIE cells with insulin (5 nM) led to only an approx. 3-fold increase of ERK2 activity in H4IIE cells after 10 min, which correlates with previously published data [15] . The activation of ERK2 by insulin was suppressed by U0126 and PD98059. No elevated ERK2 activity could be detected after an incubation for 120 min with insulin. In H4IIE cells PMA activated PKB only slightly (Table 5 ). In parallel incubations insulin led to an approx. 7-fold increase of PKB activity after 120 min, which was blocked by the PI 3-kinase inhibitor LY294002, as described previously [5] . The administration of Bt # cAMP and dexamethasone does not increase PKB activity in H4IIE cells [5] . These results indicate that in H4IIE cells PMA strongly activates the ERK pathway, but only slightly activates the PI 3-kinase pathway. However, insulin activates the PI 3-kinase pathway, but stimulates it to a much lesser extent than PMA stimulates the MEK\ERK pathway.
IRU does not mediate the regulation of the G6Pase promoter by PMA
The effect of insulin on G6Pase gene expression is, in part, mediated by the IRU between nt k196 and k156 of the G6Pase promoter [5, 8] . In order to study a potential involvement of this cis-active structure in the regulation via the activated MEK\ERK cascade, we compared the PMA effect on the wild-type G6Pase promoter with that on a construct with a mutated IRU. No significant difference of the regulation of basal ( Figure 4A ) and induced gene expression ( Figure 4B ) between the construct G6Pase(k1227\j57) and the mutated construct G6Pase(k1227\j57\IRUmut) was detected. In parallel experiments the mutation of the forkhead-binding sites impaired the insulin effect on the promoter activity by approx. 20-30 %, as has been shown previously [5] . The data indicate that the forkhead-binding sites within the IRU of the G6Pase promoter are not significantly involved in the regulation of the G6Pase promoter activity by PMA or the MEK\ERK cascade.
Figure 4 Mutation of the forkhead-binding sites of the IRU does not impair the suppression of basal (A) and Bt 2 cAMP/dexamethasone-induced (B)
G6Pase promoter activity by PMA H4IIE cells were co-transfected with 0.5 µg/dish of pRL control plasmid together with either 8.5 µg/dish of either the promoter plasmids G6Pase(k1227/j57) or G6Pase(k1227/j57/IRUmut). Within the construct G6Pase(k1227/j57/IRUmut) the forkhead-binding sites of the IRU were mutated from k196 5h-CGATCAGGCTGTTTTTGTG-TGCCTGTTTTTCTATTTTACG-3h k156 into 5h-CGATCAGGCTCGAGTTGTGTGCCTCTTTTTCT-CTTTTACG-3h (mutated nucleotides are underlined) [5] . 
DISCUSSION
In the present study we have demonstrated that PMA and insulin decrease basal and induced G6Pase gene expression by different signalling pathways. PMA acts via the MEK\ERK cascade, whereas the effect of insulin is transferred by PI 3-kinase [4] . This assumption correlates with the different abilities of PMA and insulin to activate ERK and PKB. PMA strongly stimulated ERK, whereas insulin displayed only a weak effect on ERK activity. In addition, we show that in H4IIE cells PMA activates ERK transiently, as has been described previously for other cellular systems [20, 21] . This indicates that a permanent stimulation of the MEK\ERK module is not required for the sustained inhibition of G6Pase gene expression by PMA. With that, the activation of MEK and ERK might be involved in initial steps of the gene regulation by PMA. Furthermore, we found a reduced stimulation of ERK2 activity by PMA in the presence of Bt # cAMP and dexamethasone. This might be caused by the described inhibition of Raf and Ras function by cAMP-activated protein kinase A [11, 12] . The activation of PI 3-kinase by PMA is cell-type dependent [13] . PI 3-kinase activation stimulates that of PKB via 3-phosphoinositide-dependent kinase 1 [6, 7] . The observation, that PKB is only slightly stimulated by PMA, indicates that in H4IIE cells this compound is a much weaker stimulant of PI 3-kinase signalling than insulin.
The experiments with the structurally and mechanistically different MEK inhibitors PD98059 and U0126 indicate that the activation of MEK is indispensable for at least the major part of the PMA effect on G6Pase gene trancription. This assumption is supported by the overexpression of the dominant negative MEK-SA222 construct and of MKP-1 (Tables 2 and 3 ). However, these constructs were able to block the regulation of the basal promoter activity by PMA completely, but suppressed the effect of PMA on the induced gene transcription only in part. In contrast with this, the MEK inhibitors fully blocked the effect of PMA on both basal and induced promoter activity. The reason for this discrepancy is not clear. A possible explanation could be that the induction of promoter activity is partly inhibited by an additional pathway besides the MEK\ERK cascade, which is also activated by PMA. This unidentified pathway could be non-specifically suppressed by the MEK inhibitors, but not by the overexpression of MKP-1 and MEK-SA222. The observation that PMA inhibits the induced G6Pase promoter activity to a higher extent than basal level expression may support the speculation that an additional pathway may be involved. The activation of the MAPK cascade can be impaired by PI 3-kinase inhibitors [6] . This mechanism could account for the slight effect of LY294002 on the regulation of G6Pase promoter activity by PMA (Table 1) .
PMA regulates not only the G6Pase promoter activity, but also the levels of endogenous G6Pase mRNA transcript by the activation of MEK. In addition, we observed that PD98059 increased the level of G6Pase mRNA transcript, but not the promoter activity. The reason for this is unclear. G6Pase gene expression is also regulated by post-transcriptional events [22] . We speculate that PD98059 interacts with a mechanism regulating G6Pase mRNA stability. The inability of U0126 to induce G6Pase expression may suggest that MEK is not involved in this mechanism.
The substrates of ERK, which lead to the suppression of G6Pase gene transcription, are unknown. ERK can stimulate kinases, such as MAPK signal integrating kinase-1 and mitogenand stress-activated protein kinase-1 [12] . Activated ERK is translocated to the nucleus, where it phosphorylates and controls several transcription factors [11, 12] . Further studies will have to establish if one of these proteins is involved in the regulation of G6Pase gene expression. The ability of PMA to decrease basal G6Pase gene expression indicates that the phorbol ester can act by means different from the modification of the glucocorticoid receptor by ERK, which has been reported in [23] . In addition, our results show that the forkhead-binding sites within the IRU, and therefore signalling via FKHR or a related transcription factor [24] , do not play considerable roles in the regulation of G6Pase gene expression by PMA. This indicates that the slight activation of PKB by PMA does not significantly contribute to the inhibition of G6Pase gene expression and provides further confirmation of the use of different signalling pathways by PMA and insulin.
Although PMA has a similar effect on the expression of the key gluconeogenic enzymes G6Pase and PEPCK, the molecular basis of the PEPCK and G6Pase gene regulation by PMA differs. The MEK\ERK cascade is not involved in the PMA regulation of PEPCK gene transcription [15] in contrast with its effect on G6Pase gene expression. Furthermore, the PMA effect on G6Pase gene transcription is not mediated by the forkhead-binding sites of the IRU. The sequence of each of these forkhead-binding sites is very similar to that of the insulin-response sequence of
